
Full profile: /officials/S001221
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
No cosponsors on record. Bills can pass without cosponsors — this often means the sponsor introduced the bill alone, either because it's a messaging bill, a chairman's mark, or simply early in the legislative cycle.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Currently in
The federal government would study how hormone levels change in women going through perimenopause (the years leading up to menopause) and evaluate the accuracy and usefulness of hormone tests during this time. The National Institutes of Health and the Department of Health and Human Services would work together to understand these hormonal changes better and determine which tests doctors should use to help women during this life stage. This research could help doctors provide better care and treatment options for women experiencing perimenopause symptoms.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.
[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 9077 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 9077 To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES May 29, 2026 Ms. Scholten introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Hormone Health Data and Research Act''. SEC. 2. STUDIES ON HORMONE VARIABILITY AND HORMONE TESTING WITH RESPECT TO PERIMENOPAUSE. (a) NIH Study.--The Director of the National Institutes of Health shall evaluate any evidence published on or prior to the date of enactment of this Act that relates to-- (1) the variability of hormone levels in a woman before such woman experiences symptoms of perimenopause; and (2) any baseline pattern in such variability. (b) U.S. Preventive Services Task Force Study.--The Secretary of Health and Human Services, acting through the United States Preventive Services Task Force, shall review any evidence published on or prior to the date of enactment of this Act related to the clinical utility of hormone testing, including whether baseline information obtained on the hormone levels of a woman before such woman experiences symptoms of perimenopause meaningfully informs the diagnosis or management of perimenopause for such woman. (c) Report.--Not later than 18 months after enactment of this Act, NIH and USPSTF shall submit a report to the Committees on Appropriations of the House of Representatives and Senate, the Committee on Energy and Commerce of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions of the Senate summarizing findings, identifying evidence gaps, and providing recommendations for future research or clinical guidance. <all>
Bills by the same sponsor or covering overlapping subjects.